Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.

Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, Cornec-Le Gall E, Claisse G, Elias M, El Karoui K, Chauvet S, Coindre JP, Rerolle JP, Tricot L, Sayegh J, Garrouste C, Charasse C, Delmas Y, Massy Z, Hourmant M, Servais A, Loirat C, Fakhouri F, Pouteil-Noble C, Peraldi MN, Legendre C, Rondeau E, Le Quintrec M, Frémeaux-Bacchi V.

J Am Soc Nephrol. 2019 Oct 1. pii: ASN.2019040331. doi: 10.1681/ASN.2019040331. [Epub ahead of print]

PMID:
31575699
2.

Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen.

Milcent B, Josseaume N, Petitprez F, Riller Q, Amorim S, Loiseau P, Toubert A, Brice P, Thieblemont C, Teillaud JL, Sibéril S.

Sci Rep. 2019 Sep 17;9(1):13471. doi: 10.1038/s41598-019-50029-y.

3.

Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology.

Sturm G, Finotello F, Petitprez F, Zhang JD, Baumbach J, Fridman WH, List M, Aneichyk T.

Bioinformatics. 2019 Jul 15;35(14):i436-i445. doi: 10.1093/bioinformatics/btz363.

4.

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.

Roumenina LT, Daugan MV, Noé R, Petitprez F, Vano YA, Sanchez-Salas R, Becht E, Meilleroux J, Clec'h BL, Giraldo NA, Merle NS, Sun CM, Verkarre V, Validire P, Selves J, Lacroix L, Delfour O, Vandenberghe I, Thuilliez C, Keddani S, Sakhi IB, Barret E, Ferré P, Corvaïa N, Passioukov A, Chetaille E, Botto M, de Reynies A, Oudard SM, Mejean A, Cathelineau X, Sautès-Fridman C, Fridman WH.

Cancer Immunol Res. 2019 Jul;7(7):1091-1105. doi: 10.1158/2326-6066.CIR-18-0891. Epub 2019 Jun 4.

PMID:
31164356
5.

Tertiary lymphoid structures in the era of cancer immunotherapy.

Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH.

Nat Rev Cancer. 2019 Jun;19(6):307-325. doi: 10.1038/s41568-019-0144-6. Review.

PMID:
31092904
6.

Impact of hypertensive emergency and complement rare variants on presentation and outcome of atypical hemolytic uremic syndrome.

El Karoui K, Boudhabhay I, Petitprez F, Vieira-Martins P, Fakhouri F, Zuber J, Aulagnon F, Matignon M, Rondeau E, Mesnard L, Halimi JM, Frémeaux-Bacchi V.

Haematologica. 2019 Mar 19. pii: haematol.2019.216903. doi: 10.3324/haematol.2019.216903. [Epub ahead of print]

7.

Revisiting immune escape in colorectal cancer in the era of immunotherapy.

Ijsselsteijn ME, Petitprez F, Lacroix L, Ruano D, van der Breggen R, Julie C, Morreau H, Sautès-Fridman C, Fridman WH, de Miranda NFDCC.

Br J Cancer. 2019 Apr;120(8):815-818. doi: 10.1038/s41416-019-0421-x. Epub 2019 Mar 13.

8.

Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells.

Dajon M, Iribarren K, Petitprez F, Marmier S, Lupo A, Gillard M, Ouakrim H, Victor N, Vincenzo DB, Joubert PE, Kepp O, Kroemer G, Alifano M, Damotte D, Cremer I.

Oncoimmunology. 2018 Oct 11;8(1):e1505174. doi: 10.1080/2162402X.2018.1505174. eCollection 2019.

9.

The clinical role of the TME in solid cancer.

Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C.

Br J Cancer. 2019 Jan;120(1):45-53. doi: 10.1038/s41416-018-0327-z. Epub 2018 Nov 9. Review.

PMID:
30413828
10.

Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine.

Petitprez F, Sun CM, Lacroix L, Sautès-Fridman C, de Reyniès A, Fridman WH.

Front Oncol. 2018 Sep 25;8:390. doi: 10.3389/fonc.2018.00390. eCollection 2018. Review.

11.

Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.

Weinstein AM, Giraldo NA, Petitprez F, Julie C, Lacroix L, Peschaud F, Emile JF, Marisa L, Fridman WH, Storkus WJ, Sautès-Fridman C.

Cancer Immunol Immunother. 2019 Jan;68(1):109-120. doi: 10.1007/s00262-018-2259-0. Epub 2018 Oct 12.

PMID:
30315348
12.

Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.

Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, Luciani A, Amaddeo G, Derman J, Charpy C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C.

J Hepatol. 2019 Jan;70(1):58-65. doi: 10.1016/j.jhep.2018.09.003. Epub 2018 Sep 11.

PMID:
30213589
13.

Immune-based identification of cancer patients at high risk of progression.

Vano YA, Petitprez F, Giraldo NA, Fridman WH, Sautès-Fridman C.

Curr Opin Immunol. 2018 Apr;51:97-102. doi: 10.1016/j.coi.2018.03.005. Epub 2018 Mar 16. Review.

PMID:
29554496
14.

Probing instructions for expression regulation in gene nucleotide compositions.

Bessière C, Taha M, Petitprez F, Vandel J, Marin JM, Bréhélin L, Lèbre S, Lecellier CH.

PLoS Comput Biol. 2018 Jan 2;14(1):e1005921. doi: 10.1371/journal.pcbi.1005921. eCollection 2018 Jan.

15.

Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies.

Petitprez F, Vano YA, Becht E, Giraldo NA, de Reyniès A, Sautès-Fridman C, Fridman WH.

Cancer Immunol Immunother. 2018 Jun;67(6):981-988. doi: 10.1007/s00262-017-2058-z. Epub 2017 Sep 7. Review.

PMID:
28884365
16.

PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer.

Petitprez F, Fossati N, Vano Y, Freschi M, Becht E, Lucianò R, Calderaro J, Guédet T, Lacroix L, Rancoita PMV, Montorsi F, Fridman WH, Sautès-Fridman C, Briganti A, Doglioni C, Bellone M.

Eur Urol Focus. 2019 Mar;5(2):192-196. doi: 10.1016/j.euf.2017.05.013. Epub 2017 Jun 21.

PMID:
28753812
17.

C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.

Marinozzi MC, Chauvet S, Le Quintrec M, Mignotet M, Petitprez F, Legendre C, Cailliez M, Deschenes G, Fischbach M, Karras A, Nobili F, Pietrement C, Dragon-Durey MA, Fakhouri F, Roumenina LT, Fremeaux-Bacchi V.

Kidney Int. 2017 Nov;92(5):1232-1241. doi: 10.1016/j.kint.2017.04.017. Epub 2017 Jul 14.

PMID:
28712854
18.

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.

Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, Sanchez-Salas R, Ingels A, Oudard S, Moatti A, Buttard B, Bourass S, Germain C, Cathelineau X, Fridman WH, Sautès-Fridman C.

Clin Cancer Res. 2017 Aug 1;23(15):4416-4428. doi: 10.1158/1078-0432.CCR-16-2848. Epub 2017 Feb 17.

19.

Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy.

Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, Choukroun G, Delmas Y, Guerrot D, François A, Le Quintrec M, Javaugue V, Ribes D, Vrigneaud L, Arnulf B, Goujon JM, Ronco P, Touchard G, Bridoux F.

Blood. 2017 Mar 16;129(11):1437-1447. doi: 10.1182/blood-2016-08-737163. Epub 2017 Jan 9.

PMID:
28069603
20.

Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A.

Genome Biol. 2016 Dec 1;17(1):249. No abstract available.

21.

Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A.

Genome Biol. 2016 Oct 20;17(1):218. Erratum in: Genome Biol. 2016 Dec 1;17 (1):249.

Supplemental Content

Loading ...
Support Center